Table 1.
Correlation between CD46 expression and clinico-pathological features in patients with bladder cancer.
| Variables | All Patients (n = 59) | Low CD46 (n = 31) | High CD46 (n = 28) | p-Value * |
|---|---|---|---|---|
| Age (IQR) | 72.7 (63.4–78.3) | |||
| ≤73 | 30 (50.8) | 16 (51.6) | 14 (50.0) | 0.902 |
| >73 | 29 (49.2) | 15 (48.4) | 14 (50.0) | |
| Sex (n, %) | ||||
| Male | 46 (78.0) | 27 (87.1) | 19 (67.9) | 0.075 |
| Female | 13 (22.0) | 4 (12.9) | 9 (32.1) | |
| BMI (kg/m2, IQR) | 24.0 (22.0–26.1) | |||
| <25 | 37 (62.7) | 18 (58.1) | 19 (67.9) | 0.437 |
| ≥25 | 22 (37.3) | 13 (41.9) | 9 (32.1) | |
| ASA score | ||||
| 1 | 6 (10.2) | 2 (6.5) | 4 (14.3) | 0.503 |
| 2 | 47 (79.7) | 25 (80.6) | 22 (78.6) | |
| 3 | 6 (10.2) | 4 (12.9) | 2 (7.1) | |
| DM (n, %) | 12 (20.3) | 6 (19.4) | 6 (21.4) | 0.843 |
| Hypertension (n, %) | 32 (54.2) | 21 (67.7) | 11 (39.3) | 0.028 ** |
| Tumor size (cm, IQR) | 1.5 (1.0–3.0) | |||
| T stage (n, %) | ||||
| Ta | 34 (57.6) | 14 (45.2) | 20 (71.4) | 0.017 ** |
| T1 | 23 (39.0) | 17 (54.8) | 6 (21.4) | |
| CIS | 2 (3.4) | 0 (0) | 2 (7.1) | |
| Grade (n, %) | ||||
| Low | 32 (54.2) | 12 (38.7) | 20 (71.4) | 0.012 ** |
| High | 27 (45.8) | 19 (61.3) | 8 (28.6) | |
| Multifocality (n, %) | 21 (35.6) | 9 (29.0) | 12 (42.9) | 0.268 |
| Concomitant CIS (n, %) | 3 (5.1) | 1 (3.2) | 2 (7.1) | 0.494 |
| EORTC risk group (n, %) | ||||
| Low | 21 (35.6) | 8 (25.8) | 13 (46.4) | 0.042 ** |
| Intermediate | 11 (18.6) | 4 (12.9) | 7 (25.0) | |
| High | 27 (45.8) | 19 (61.3) | 8 (28.6) | |
| Intravesical Chemotherapy (n, %) | ||||
| No | 42 (71.2) | 22 (71.0) | 20 (71.4) | 0.129 |
| BCG | 14 (23.7) | 9 (29.0) | 5 (17.9) | |
| Adriamycin | 3 (5.1) | 0 (0) | 3 (10.7) | |
| Recurrence (n, %) | 26 (44.1) | 16 (51.6) | 10 (35.7) | 0.219 |
*, Pearson’s χ2 test was used; **, statistically significant; IQR, interquartile range; BMI, body mass index; ASA score, American society of anesthesiologists score; DM, diabetes mellitus; CIS, carcinoma in situ; EORTC, European organisation for research and treatment of cancer; BCG, bacille Calmette-Guerin.